At AstraZeneca, we know that the life-changing medicines we develop will not have an impact on healthcare in the United States if patients are unable to access them. That’s why for more than 35 years we have helped patients afford the medicines they rely on through our patient assistance programs. In 2014, AstraZeneca continued to fulfill our promise to support patients by providing more than $670 million in savings to nearly 383,000 patients in the United States through our AZ&Me Prescription Savings Programs.
This suite of programs is designed to help qualifying people without insurance, those enrolled in Medicare Part D, those who receive their medications through participating health care facilities and those who have faced a financial challenge recently.
“As seen with the recent Supreme Court ruling to uphold healthcare subsidies, the discussions around healthcare in the United States continue to evolve. We remain committed to offering our patient assistance programs as this dialogue progresses,” said Diane Sullivan, Vice President, Market Access & Patient Strategies. “We believe it’s not enough for us to simply make great medicines. We have to help ensure that the people who need those medicines have access to them.”
The healthcare landscape will continue to shift, but AstraZeneca is dedicated to helping patients afford their medicines, even if they aren’t ours. We participate in multi-manufacturer programs like the Partnership for Prescription Assistance and support other organizations with the same goal—increasing access to medicines as well as health care.
Jennifer McGovern, Director of Affordability Programs at AstraZeneca, explains the impact our patient assistance programs have in this video:
As we continue to follow the science to advance research and develop new medicines, the end results of these efforts are always focused on improving patient health and outcomes. Learn more about the AZ&Me Prescription Savings Programs here, or call 1-800-AZandMe (292-6363).